(Z)-2-(trimethylsilyl)ethyl N,N′-diisopropylcarbamimidate | 146009-80-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 甲亚胺酸及其衍生物
• 英文名称: (Z)-2-(trimethylsilyl)ethyl N,N′-diisopropylcarbamimidate
• 英文别名: O-(2-trimethylsilyl)ethyl-N,N'-diisopropylisourea；2-trimethylsilylethyl-N,N-diisopropyl-pseudourea
• CAS: 146009-80-5
• 化学式: C12H28N2OSi
• 分子量: 244.45
• InChiKey: FDBHLWPAYLFTLI-UHFFFAOYSA-N

物化性质

• 沸点：
  334.1±25.0 °C(Predicted)
• 密度：
  0.88±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  33.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (Z)-2-(trimethylsilyl)ethyl N,N′-diisopropylcarbamimidate 、 N-乙酰基-D-青霉胺 生成 N-acetyl-3-(nitrosothio)-D-valine 2-trimethylsilylethyl ester
  参考文献：
  名称：

  S-nitroso-N-alkonoylpenicillamines

  摘要：

  本发明涉及式(I)的化合物，其中R1是C1-8烷基；C5-8环烷基；--(CH2)n--Si(CH3)3，其中n为1至5；C2-5烷基亚基；芳基甲亚基；芳基；杂芳基；或其中所述的芳基或杂芳基独立地带有1至3个取代基，所述取代基选自卤素，氨基，C1-8烷基单取代或双取代氨基，C1-8烷基和C1-8烷氧基，R2是C1-8烷氧基，以及包含这些化合物的制药配方和它们作为血管扩张剂和治疗心血管疾病的用途。

  公开号：

  US05187305A1

文献信息

• [EN] C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS<br/>[FR] AMIDES C-28 DE DÉRIVÉS D'ACIDE BÉTULINIQUE MODIFIÉS EN C-3, UTILISÉS COMME INHIBITEURS DE MATURATION DU VIH
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011153319A1

  公开（公告）日：2011-12-08

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 and C-28 betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.

  具有药物和生物活性的化合物、其药物组合物及其使用方法。特别是，提供了一种具有独特抗病毒活性的改性C-3和C-28桦木酸衍生物，用作HIV成熟抑制剂。这些化合物可用于治疗HIV和艾滋病。
• [EN] TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY, SUBSTITUTED IN POSITION 3 BY A NON-AROMATIC RING CARRYING A HALOALKYL SUBSTITUENT<br/>[FR] TRITERPÉNOÏDES PRÉSENTANT UNE ACTIVITÉ D'INHIBITION DE LA MATURATION DU VIH, SUBSTITUÉS EN 3ÈME POSITION PAR UN CYCLE NON AROMATIQUE PORTANT UN SUBSTITUANT HALOGÉNOALKYLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015157483A1

  公开（公告）日：2015-10-15

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from C4-8 cycloalkyl, C4-8 cycloalkenyl, C4-9 spirocycloalkyl, C4-9 spirocycloalkenyl, C4-8 oxacycloalkyl, C4-8 dioxacycloalkyl, C6-8 oxacycloalkenyl, C6-8 dioxacycloalkenyl, C6 cyclodialkenyl, C6 oxacyclodialkenyl, C6-9 oxaspirocycloalkyl and C6-9 oxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is -C1-6 alkyl- halo. These compounds are useful for the treatment of HIV and AIDS.

  具有药物和生物活性的化合物、其药物组合物及其用途被详细阐述。特别是，提供了一种具有独特抗病毒活性的三萜类化合物，作为HIV成熟抑制剂，由公式I的化合物表示：其中X选自C4-8环烷基、C4-8环烯基、C4-9螺环烷基、C4-9螺环烯基、C4-8氧环烷基、C4-8二氧环烷基、C6-8氧环烯基、C6-8二氧环烯基、C6二烯基、C6氧二烯基、C6-9氧螺环烷基和C6-9氧螺环烯基环，使得X被A取代，其中A是- C1-6烷基-卤素。这些化合物用于治疗HIV和艾滋病。
• C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY
  申请人：Bristol-Myers Squibb Company

  公开号：US20130210787A1

  公开（公告）日：2013-08-15

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-3 cycloalkenyl triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II, III and IV: wherein X can be a C 4-8 cycloalkyl, C 4-8 cycloalkenyl, C 4-9 spirocycloalkyl, C 4-9 spirocycloalkenyl, C 4-8 oxacycloalkyl, C 4-8 dioxacycloalkyl, C 6-8 oxacycloalkenyl, C 6-8 dioxacycloalkenyl, C 6-9 oxaspirocycloalkyl, or C 6-9 oxaspirocycloalkenyl ring. These compounds are useful for the treatment of HIV and AIDS.

  具有药物和生物活性的化合物、其药物组合物及其用途被详细说明。特别是，提供了具有独特抗病毒活性的C-3环烯三萜类化合物，作为HIV成熟抑制剂，由公式I、II、III和IV所示的化合物代表： 其中X可以是C4-8环烷基，C4-8环烯基，C4-9螺环烷基，C4-9螺环烯基，C4-8氧杂环烷基，C4-8二氧杂环烷基，C6-8氧杂环烯基，C6-8二氧杂环烯基，C6-9氧杂螺环烷基或C6-9氧杂螺环烯基环。这些化合物用于治疗HIV和艾滋病。
• Bryophyte Constituents; 7: New Synthesis of (+)-Rosmarinic Acid and Related Compounds
  作者：Theophil Eicher、Markus Ott、Andreas Speicher

  DOI：10.1055/s-1996-4289

  日期：1996.6

  Efficient and expeditious syntheses are described for rosmarinic acid (1) and its derivatives 2-4, making extensive use of allyl protective groups for both carboxylic acids and phenolic building blocks. (+)-(R)-Rosmarinic acid was obtained by a chemoenzymatic resolution of its phenyl lactic acid precursors.

  描述了迷迭香酸（1）及其衍生物2-4的高效快捷合成方法，广泛采用了烯丙基保护基团用于羧酸和酚类构建单元。通过化学酶促拆分其苯基乳酸前体，获得了(+)-(R)-迷迭香酸。
• Oxathi(SIV)azol-5-one compounds
  申请人：Glaxo Inc.

  公开号：US05087631A1

  公开（公告）日：1992-02-11

  The present invention relates to the compounds of formula (I). ##STR1## wherein R.sup.1 is C.sub.1-8 alkyl, C.sub.2-8 alkenyl, C.sub.5-8 cycloalkyl, aryl-C.sub.1-4 alkyl, aryl or heteroaryl; or aryl or heteroaryl which is mono-, di-, or trisubstituted independently with halogen, nitro, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl, amino or C.sub.1-4 alkyl mono or disubstituted amino, pharmaceutical formulations containing these compounds and their use as vasodilators in the treatment of cardiovascular disorders.

  本发明涉及式（I）的化合物。其中R.sup.1为C.sub.1-8烷基，C.sub.2-8烯基，C.sub.5-8环烷基，芳基-C.sub.1-4烷基，芳基或杂环芳基；或者芳基或杂环芳基独立地与卤素，硝基，C.sub.1-4烷基，C.sub.1-4烷氧基，三氟甲基，氨基或C.sub.1-4烷基单取代或双取代氨基进行单取代，二取代或三取代；包含这些化合物的药物制剂以及它们作为血管扩张剂在治疗心血管疾病中的用途。